Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 215-170-3 | CAS number: 1309-42-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Exposure related observations in humans: other data
Administrative data
- Endpoint:
- exposure-related observations in humans: other data
- Type of information:
- experimental study
- Adequacy of study:
- disregarded due to major methodological deficiencies
- Reliability:
- 3 (not reliable)
- Rationale for reliability incl. deficiencies:
- significant methodological deficiencies
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 987
Materials and methods
- Endpoint addressed:
- basic toxicokinetics
- acute toxicity: oral
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- - Principle of test:
Examination of the bioavailability of magnesium following a large oral dose of magnesium sulphate in volunteers.
- Short description of test conditions: Seven healthy men who had not taken any medication for at least a week were chosen for this study and administered a cathartic dose of magnesium sulphate orally. Urinary excretion of magnesium was then monitored over a 72-hour period. Urine samples were collected at approximately 4-hour intervals during the day and over 8 hours at night.
- Parameters analysed / observed: Baseline 24-hour excretion rates were calculated for each subject by averaging the results of each of the 3 consecutive 24-hour urine collections during the control week. - GLP compliance:
- no
Test material
- Reference substance name:
- Magnesium sulphate
- EC Number:
- 231-298-2
- EC Name:
- Magnesium sulphate
- Cas Number:
- 7487-88-9
- Molecular formula:
- H2O4S.Mg
- IUPAC Name:
- Magnesium Sulphate
Constituent 1
- Specific details on test material used for the study:
- Magnesium sulphate, USP was administered. This is the heptahydrate salt. It is equivalent to 6.8 g of anhydrous salt, or 56.5 mmoles.
Method
- Ethical approval:
- not specified
- Details on study design:
- Seven healthy men who had not taken any medication for at least a week were chosen for this study and administered a cathartic dose of magnesium sulphate orally. Urinary excretion of magnesium was then monitored over a 72-hour period. Urine samples were collected at approximately 4-hour intervals during the day and over 8 hours at night. They were frozen immediately.
For assay, the samples were allowed to defrost, and then they were shaken. They were centrifuged for 2 minutes. The supernatant was diluted and then assayed by atomic absorption spectrophotometry. The precipitate was dissolved in 1N HCl and the mean magnesium content was determined.
Baseline 24-hour excretion rates were calculated for each subject by averaging the results of each of the 3 consecutive 24-hour urine collections during the control week. These could then be subtracted from the results obtained during the experimental week to correct for endogenous magnesium. - Exposure assessment:
- measured
- Details on exposure:
- TYPE OF EXPOSURE: oral
During the experimental week, subjects received 13.9 g magnesium sulfate, USP (the heptahydrate salt, equivalent to 6.8 g of anhydrous salt, or 56.5 mmoles) in four divided portions of 3.48 g in 100 mL water at one-hour intervals after a light, low-fat breakfast. During the control week, the subjects received only the four aliquots of 100 mL water at one-hour intervals. The order of the treatment and control weeks was randomized.
Results and discussion
- Results:
- About 4% of 56.5 mmol (13.9 g) oral dose of magnesium sulfate is absorbed in healthy volunteers. All of the subjects experienced mild or moderate diarrhea. Therefore, magnesium is absorbed to a limited and variable extent in healthy adults following a cathartic dose of magnesium sulfate.
Any other information on results incl. tables
The urine from one subject was lost during transit and sample work-up.
The baseline excretion rate of magnesium for the remaining six subjects was (mean±SD) 4.4±1.1 mmoles/day (range of means: 3.0-6.0) with a coefficient of variation (based on the
three control days) of 21.3±8.72 (range: 9.1-31.7%). Creatinine excretion rates ranged from 12.4 to 18.7 mmoles/day with a coefficient of variation for individual subjects of 9.4±4.8%.
Baseline magnesium excretion rates were significantly correlated with baseline creatinine excretion rates (r=0.875, p<0.05). The intersubject variability in the 24-hour excretion rate of magnesium was not significantly reduced by normalizing the baseline excretion rate for either body weight or estimated body surface area (not reported) but was decreased when magnesium excretion rates were normalized for creatinine excretion rates.
The urinary excretion of magnesium during the first 24 hours after administration of magnesium sulfate, corrected for baseline excretion, was 4.0±2.9% of the dose (range: 0.8-8.7%). The cumulative average of the 48-hour and 72-hour periods were 5.9±4.7% and 6.9±7.0%, respectively. The 24-hour excretion rate of magnesium was significantly increased in 5 of the 6 subjects after magnesium sulfate ingestion. The excretion rate of creatinine during the treated period was essentially identical with that of the baseline value (mean±SD of individual excretion rate ratios, 1 .0±0.1).
The increase in the urinary excretion rates of magnesium after the ingestion of magnesium sulphate allows an estimation of the extent of absorption of this ion. While only 4.0±2.9% of the dose of magnesium was absorbed, 30.2±17.2% of the dose of inorganic sulphate was absorbed. All six subjects reported adverse gastrointestinal effects after magnesium sulphate ingestion. Two subjects experienced mild while four subjects experienced more severe diarrhea that began 3 to 11 hours after magnesium sulphate ingestion.
Table 1: Comparison of the Urinary Excretion of Magnesium and Sulfate after Oral Administration of 13.9 g Magnesium sulphate
Variable | Magnesium | Sulphate | ||
Number of subjects | 6 | 7 | ||
mean | SD | mean | SD | |
Age | 28.2 | 6.7 | 28.7 | 6.3 |
Body weight | 77.1 | 5.4 | 75.8 | 6.0 |
Baseline Excretion Rate | ||||
(mmol/day) | 4.4 | 1.0 | 23.8 | 4.2 |
(mmol/70 kg/day) | 4.0 | 0.9 | 22.0 | 3.8 |
Baseline Excretion Ratio, ion/creatinine | 0.27 | 0.03 | 1.5 | 0.14 |
Cumulative Excretion of Ions (%of Dose) | ||||
24 hours | 4.0 | 2.9 | 30.2 | 17.2 |
48 hours | 5.9 | 4.7 | 35.4 | 24.6 |
72 hours | 6.9 | 7.0 | 37.5 | 26.9 |
Table 2: Individual 24 -Hour Urinary Excretion Rates of Magnesium after Oral Administration of 13.9 g Magnesium sulphate(a)
Magnesium Excretion(b) (mmol/day) | Urinary Magnesium/Creatinine Ratio | |||
Subject | Baseline | Treated | Baseline | Treated |
1 | 3.8 (0.7) | 4.7(c) | 0.26 (0.02) | 0.33(c) |
2 | 4.7 (0.8) | 5.1 | 0.28 (0.05) | 0.29 |
3 | 3.0 (0.9) | 5.3(c) | 0.25 (0.08) | 0.38(c) |
4 | 6.0 (1.9) | 10.9(c) | 0.33 (0.11) | 0.62(c) |
5 | 4.5 (0.4) | 7.9(c) | 0.24 (0.01) | 0.46(c) |
6 | 4.5 (0.9) | 6.3(c) | 0.26 (0.05) | 0.36(c) |
(a) Results expressed as mean (SD)
(b) Amount excreted in the first 24 hours after magnesium sulphate
(c) Significantly different from baseline (p<0.05) by a two-tailed Z-test.
Applicant's summary and conclusion
- Conclusions:
- About 4% of 56.5 mmol (13.9 g) oral dose of magnesium sulfate is absorbed in healthy volunteers. All of the subjects experienced mild or moderate diarrhea. Therefore, magnesium is absorbed to a limited and variable extent in healthy adults following a cathartic dose of magnesium sulfate.
- Executive summary:
In a publication from Morris et al., the bioavailability of magnesium following magnesium sulphate in normal volunteers was examined. Seven healthy men who had not taken any medication for at least a week were chosen for this study and administered a cathartic dose of magnesium sulphate orally. Urinary excretion of magnesium was then monitored over a 72-hour period. Urine samples were collected at approximately 4-hour intervals during the day and over 8 hours at night. Baseline 24-hour excretion rates were calculated for each subject by averaging the results of each of the 3 consecutive 24-hour urine collections during the control week.
About 4% of 56.5 mmol (13.9 g) oral dose of magnesium sulfate is absorbed in healthy volunteers. All of the subjects experienced mild or moderate diarrhea. Therefore, magnesium is absorbed to a limited and variable extent in healthy adults following a cathartic dose of magnesium sulfate.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.